The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kovalenko E.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Makhnovich E.V.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Pervunina A.V.

Pirogov Russian National Research Medical University (Pirogov University)

Gileva E.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Bogolepova A.N.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids

Authors:

Kovalenko E.A., Makhnovich E.V., Pervunina A.V., Gileva E.A., Bogolepova A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1): 8‑16

DOI: 10.17116/jnevro20251250118

Views: 631

Downloaded: 4

Buy for 300₽
Contact the author
Table of contents

NON-INVASIVE BIOMARKERS FOR EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE IN BODILY FLUIDS
NON-INVASIVE BIOMARKERS FOR EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE IN BODILY FLUIDS

To cite this article:

Kovalenko EA, Makhnovich EV, Pervunina AV, Gileva EA, Bogolepova AN. Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):8‑16. (In Russ.)
https://doi.org/10.17116/jnevro20251250118

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Glymphatic dysfunction and sleep diso­rders: indi­rect effe­cts on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12
Ginkgolide B: mechanisms of neurobiological effe­cts, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27
A comparative asse­ssment of microbiocenosis of saliva and oropharynx in patients with migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):55-62
Prevalence of cognitive impairment in older adults in the Russian Fede­ration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24
Impairment of atte­ntion and executive functions in chro­nic cere­brovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32
Asse­ssment of the significance of dila­ted peri­vascular spaces and nocture arte­rial hype­rtension in the deve­lopment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40
Cognitive impairment in patients with arte­rial hype­rtension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48
EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

One of the urgent problems of modern health care is Alzheimer’s disease (AD) and its early diagnosis. This is due to the rapid global spread of AD, the lack of pathogenetic therapy, and the ability to stabilize the progression of cognitive impairment in the early stages of the disease. Currently, only an autopsy can confirm the diagnosis of AD with 100% reliability, and classical laboratory and instrumental methods of diagnosis verification are difficult to implement in routine clinical practice due to several limitations. That is why the study of new and available biomarkers identified in human bodily fluids is promising for the early diagnosis of AD. The review addresses the problem of AD verification using markers in human bodily fluids, which can be obtained in a non-invasive way. Potential biomarkers of AD in saliva, tear fluid, urine, and nasal secretion are reviewed, and their prognostic values as AD indicators in the early stage are evaluated.

Keywords:

dementia
cognitive impairment
Alzheimer’s disease
non-invasive biomarkers
saliva
tear
urine
nasal secretion

Authors:

Kovalenko E.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Makhnovich E.V.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Pervunina A.V.

Pirogov Russian National Research Medical University (Pirogov University)

Gileva E.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Bogolepova A.N.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Received:

23.07.2024

Accepted:

25.07.2024

List of references:

  1. Hane FT, Robinson M, Lee BY, et al. Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment. J Alz Dis. 2017;57(3):645-665.  https://doi.org/10.3233/JAD-160907
  2. Bălașa AF, Chircov C, Grumezescu AM. Body Fluid Biomarkers for Alzheimer’s Disease-An Up-To-Date Overview. Biomedicines. 2020;15:8(10):421.  https://doi.org/10.3390/biomedicines8100421
  3. Dos Santos Picanco LC, Ozela PF, et al. Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Curr Med Chem. 2018;25:3141-3159. https://doi.org/10.2174/0929867323666161213101126
  4. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. The Lancet Neurology. 2021;20(6):484-496.  https://doi.org/10.1016/S1474-4422(21)00066-1
  5. Romaus-Sanjurjo D, Regueiro U, López-López M, et al. Alzheimer’s Disease Seen through the Eye: Ocular Alterations and Neurodegeneration. Int J Mol Sci. 2022;23(12):2486. https://doi.org/10.3390/ijms23052486
  6. Ashton NJ, Ide M, Zetterberg H, Blennow K. Salivary Biomarkers for Alzheimer’s Disease and Related Disorders. Neurol Ther. 2019;8:83-94.  https://doi.org/10.1007/s40120-019-00168-1
  7. Bermejo-Pareja F, Antequera D, Vargas T, et al. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurology. 2010;10(7):108. 
  8. Lee M, Guo JP, Kennedy K, et al. A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels. J Alz Dis. 2017;55(3):1175-1182. https://doi.org/10.3233/JAD-160748
  9. Sabbagh MN, Shi J, Lee M, et al. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer’s disease dementia from normal controls: preliminary findings. BMC Neurology. 2018;18(1):155.  https://doi.org/10.1186/s12883-018-1160-y
  10. Gleerup HS, Hasselbalch SG, Simonsen AH. Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review. Dis Mark. 2019;2019:4761054. https://doi.org/10.1155/2019/4761054
  11. Nijakowski K, Owecki W, Jankowski J, Surdacka A. Salivary Biomarkers for Alzheimer’s Disease: A Systematic Review with Meta-Analysis. Int J Mol Sci. 2024;25(2):1168. https://doi.org/10.3390/ijms25021168
  12. Zalewska A, Klimiuk A, Zięba S, et al. Salivary Gland Dysfunction and Salivary Redox Imbalance in Patients with Alzheimer’s Disease. Sci Rep. 2021;11:23904. https://doi.org/10.1038/s41598-021-03456-9
  13. Sabaei M, Rahimian S, Haj ME, Ketabforoush A, et al. Salivary Levels of Disease-Related Biomarkers in the Early Stages of Parkinson’s and Alzheimer’s Disease: A Cross-Sectional Study. IBRO Neurosci Rep. 2023;14:285-292.  https://doi.org/10.1016/j.ibneur.2023.03.004
  14. Tvarijonaviciute A, Zamora C, Ceron JJ, et al. Salivary biomarkers in Alzheimer’s disease. Clin Oral Invest. 2020;24(10):3437-3444. https://doi.org/10.1007/s00784-020-03214-7
  15. Cui Y, Zhang H, Zhu J, et al. Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer’s Disease Diagnosis. Brain Sci. 2022;12:595.  https://doi.org/10.3390/brainsci12050595
  16. Shi M, Sui YT, Peskind ER, et al. Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alz Dis. 2011;27(2):299-305.  https://doi.org/10.3233/JAD-2011-110731
  17. Pekeles H, Qureshi HY, Paudel HK, et al. Development and validation of a salivary tau biomarker in Alzheimer’s disease. Alzheimers Dem. 2019;11:53-60.  https://doi.org/10.1016/j.dadm.2018.03.003
  18. Baker HM, Baker EN. Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals. 2004;17(3):209-216.  https://doi.org/10.1023/b:biom.0000027694.40260.70
  19. Arslan SY, Leung KP, Wu CD. The effect of lactoferrin on oral bacterial attachment. Oral Microbiol Immunol. 2009;24(5):411-416.  https://doi.org/10.1111/j.1399-302X.2009.00537.x
  20. González-Sánchez M, Bartolome F, Antequera D, et al. Decreased salivary lactoferrin levels are specific to Alzheimer’s disease. EBioMed. 2020;57:102834. https://doi.org/10.1016/j.ebiom.2020.102834
  21. Reseco L, Atienza M, Fernandez-Alvarez M, et al. Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimer’s Res Ther. 2021;13(1):150.  https://doi.org/10.1186/s13195-021-00891-8
  22. Gleerup HS, Jensen CS, Høgh P, et al. Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer’s disease in a mixed memory clinic population. EBioMed. 2021;67:103361. https://doi.org/10.1016/j.ebiom.2021.103361
  23. Thapa S, Lv M, Xu H. Acetylcholinesterase: A Primary Target for Drugs and Insecticides. Mini Rev Med Chem. 2017;17:1665-1676. https://doi.org/10.2174/1389557517666170120153930
  24. Rotundo RL. Biogenesis, assembly and trafficking of acetylcholinesterase. J Neurochem. 2017;142 Suppl 2(Suppl 2):52-58.  https://doi.org/10.1111/jnc.13982
  25. Ahmadi-Motamayel F, Goodarzi MT, Tarazi S, Vahabian M. Evaluation of Salivary Acetylcholinesterase and Pseudocholinesterase in Patients with Alzheimer’s Disease: A Case-Control Study. Special Care Dent. 2019;39:39-44.  https://doi.org/10.1111/scd.12342
  26. Bakhtiari S, Moghadam NB, Ehsani M, et al. Can Salivary Acetylcholinesterase Be a Diagnostic Biomarker for Alzheimer? J Clin Diagn Res. 2017;11:ZC58-ZC60. https://doi.org/10.7860/JCDR/2017/21715.9192
  27. Knezevic E, Nenic K, Milanovic V, Knezevic NN. The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders. Cells. 2023;12(23):2726.
  28. De Souza-Talarico JN, Caramelli P, Nitrini R, Chaves EC. Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer’s disease. Arq Neuropsiquiatr. 2008;66(3B):619-624.  https://doi.org/10.1590/s0004-282x2008000500003
  29. Peña-Bautista C, Baquero M, Ferrer I, et al. Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer’s disease patients. Exp Gerontol. 2019;123:10-16. 
  30. Katsipis G, Tzekaki EE, Tsolaki M, Pantazaki AA. Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer’s disease and its correlation with neuroinflammation and apoptosis. J Neuroimmunol. 2021;361:577744. https://doi.org/10.1016/j.jneuroim.2021.577744
  31. McNicholas K, François M, Liu JW, et al. Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer’s disease in a feasibility study. Front Aging Neurosci. 2022;14:1019296. https://doi.org/10.3389/fnagi.2022.1019296
  32. Contini C, Serrao S, Manconi B, et al. Characterization of Cystatin B Interactome in Saliva from Healthy Elderly and Alzheimer’s Disease Patients. Life (Basel, Switzerland). 2023;13(3):748.  https://doi.org/10.3390/life13030748
  33. Peña-Bautista C, Torres-Cuevas I, Baquero M, et al. Early neurotransmission impairment in non-invasive Alzheimer Disease detection. Sci Rep. 2020;10(1):16396. https://doi.org/10.1038/s41598-020-73362-z
  34. Marksteiner J, Defrancesco M, Humpel C. Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease. Front Aging Neurosci. 2022;14:1014305. https://doi.org/10.3389/fnagi.2022.1014305
  35. Ryu IS, Kim DH, Ro JY, et al. The microRNA-485-3p Concentration in Salivary Exosome-Enriched Extracellular Vesicles Is Related to Amyloid β Deposition in the Brain of Patients with Alzheimer’s Disease. Clin Biochem. 2023;118:110603. https://doi.org/10.1016/j.clinbiochem.2023.110603
  36. Pukhalskaia AE, Dyatlova AS, Linkova NS, et al. Sirtuins as Possible Predictors of Aging and Alzheimer’s Disease Development: Verification in the Hippocampus and Saliva. Bull Exp Biol Med. 2020;169(6):821-824.  https://doi.org/10.1007/s10517-020-04986-4
  37. Khalifeh M, Read MI, Barreto GE, Sahebkar A. Trehalose against Alzheimer’s Disease: Insights into a Potential Therapy. BioEssays. 2020;42:e1900195. https://doi.org/10.1002/bies.201900195
  38. Lau HC, Lee IK, Ko PW, et al. Non-Invasive Screening for Alzheimer’s Disease by Sensing Salivary Sugar Using Drosophila Cells Expressing Gustatory Receptor (Gr5a) Immobilized on an Extended Gate Ion-Sensitive Field-Effect Transistor (EG-ISFET) Biosensor. PLoS One. 2015;10:e0117810. https://doi.org/10.1371/journal.pone.0117810
  39. Haigh BJ, Stewart KW, Whelan JR, et al. Alterations in the salivary proteome associated with periodontitis. J Clin Periodontol. 2010;37(3):241-247.  https://doi.org/10.1111/j.1600-051X.2009.01525.x
  40. Al-Amrani S, Al-Jabri Z, Al-Zaabi A, et al. Proteomics: Concepts and Applications in Human Medicine. World J Biol Chem. 2021;12:57-69.  https://doi.org/10.4331/wjbc.v12.i5.57
  41. Huan T, Tran T, Zheng J, et al. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer’s Disease. J Alz Dis. 2018;65:1401-1416. https://doi.org/10.3233/JAD-180711
  42. François M, Karpe A, Liu JW, et al. Salivaomics as a Potential Tool for Predicting Alzheimer’s Disease During the Early Stages of Neurodegeneration. J Alz Dis. 2021;82(3):1301-1313. https://doi.org/10.3233/JAD-210283
  43. Liang Q, Liu H, Li X, Zhang Y. High performance liquid chromatography coupled with high resolution mass spectrometry-based characterization of lipidomic responses from rats with kidney injuries. RSC Adv. 2021;36:20250-20258. https://doi.org/10.1039/c8ra02805b
  44. Marksteiner J, Oberacher H, Humpel C. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer’s Disease as Identified by Targeted Metabolomics. J Alzheimers Dis. 2019;68(2):583-589.  https://doi.org/10.3233/JAD-181278
  45. Eldem E, Barve A, Sallin O, et al. Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion. J Alz Dis Rep. 2022;6:31-41.  https://doi.org/10.3233/ADR-210056
  46. Wan J, Fan H. Oral Microbiome and Alzheimer’s Disease. Microorganisms. 2023;11:2550. https://doi.org/10.3390/microorganisms11102550
  47. Zürcher C, Humpel C. Saliva: a challenging human fluid to diagnose brain disorders with a focus on Alzheimer’s disease. Neural Regeneration Res. 2023;18(12):2606-2610. https://doi.org/10.4103/1673-5374.373675
  48. Hu X, McKenzie CA, Smith C, et al. The remarkable complexity of the brain microbiome in health and disease. BioRxiv. 2023;2(6):527297. https://doi.org/10.1101/2023.02.06.527297
  49. Kaštelan S, Braš M, Pjevač N, et al. Tear Biomarkers and Alzheimer’s Disease. International Journal of Mol Sci. 2023;24(17):13429. https://doi.org/10.3390/ijms241713429
  50. Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome. J Proteom. 2012;75(13):3877-3885. https://doi.org/10.1016/j.jprot.2012.04.053
  51. Del Prete S, Marasco D, Sabetta R, et al. Tear Liquid for Predictive Diagnosis of Alzheimer’s Disease. Sci Rep. 2021;4(3):26.  https://doi.org/10.3390/reports4030026
  52. Wang YR, Chuang HC, Tripathi A, et al. High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of β-Amyloid in Human Blood and Tears. Analyt Chem. 2021;93(22):8099-8106. https://doi.org/10.1021/acs.analchem.0c04980
  53. Gijs M, Ramakers IHGB, Visser PJ, et al. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Sci Rep. 2021;11(1):22675.
  54. Gharbiya M, Visioli G, Trebbastoni A, et al. Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer’s Disease Correlated with Choroidal Thickness. Int J Mol Sci. 2023;24(3):2590. https://doi.org/10.3390/ijms24032590
  55. Kalló G, Emri M, Varga Z, et al. Changes in the Chemical Barrier Composition of Tears in Alzheimer’s Disease Reveal Potential Tear Diagnostic Biomarkers. PloS One. 2016;11(6):e0158000. https://doi.org/10.1371/journal.pone.0158000
  56. Kenny A, Jiménez-Mateos EM, Zea-Sevilla MA, et al. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s disease. Sci Rep. 2019;9(1):15437. https://doi.org/10.1038/s41598-019-51837-y
  57. van de Sande N, Ramakers IHGB, Visser PJ, et al. Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study. BMC Neurology. 2023;23(1):293.  https://doi.org/10.1186/s12883-023-03335-y
  58. Lim JK, Li QX, He Z, et al. The Eye as a Biomarker for Alzheimer’s Disease. Front Neurosci. 2016;10:536.  https://doi.org/10.3389/fnins.2016.00536
  59. Karki HP, Jang Y, Jung J, Oh J. Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of Alzheimer’s disease. J Nanobiotechnol. 2021;19(1):72.  https://doi.org/10.1186/s12951-021-00814-7
  60. Kurbatova N, Garg M, Whiley L, et al. Urinary metabolic phenotyping for Alzheimer’s disease. Sci Rep. 2020;10(1):21745. https://doi.org/10.1038/s41598-020-78031-9
  61. Watanabe Y, Hirao Y, Kasuga K, et al. Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease. Dementia Geriatr Cogn Disord. 2020;10(3):94-104.  https://doi.org/10.1159/000509561
  62. Monte SM, Ghanbari K, Frey WH, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer’s disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1997;100:3093-3104. https://doi.org/10.1172/JCI119864
  63. Li Y, Kang M, Sheng C, et al. Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population. Neural Plasticity. 2020;2020:9742138. https://doi.org/10.1155/2020/9742138
  64. Lv S, Zhou X, Li Y, et al. The Association Between Plasma α-Synuclein (α-syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE 4) Alleles and Cognitive Decline in 60 Patients with Alzheimer’s Disease Compared with 28 Age-Matched Normal Individuals. Med Sci Mon. 2021;27:e932998. https://doi.org/10.12659/MSM.932998
  65. Wang Y, Pan F, Xie F, et al. Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer’s Disease. Front Aging Neurosci. 2022;14:820385. https://doi.org/10.3389/fnagi.2022.820385
  66. Martinelli F, Heinken A, Henning AK, et al. Whole-body modelling reveals microbiome and genomic interactions on reduced urine formate levels in Alzheimer’s disease. Res Square. 2023;rs.3.rs-3306891. https://doi.org/10.21203/rs.3.rs-3306891/v1
  67. García-Blanco A, Peña-Bautista C, Oger C, et al. Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. Talanta. 2018;184:193-201.  https://doi.org/10.1016/j.talanta.2018.03.002
  68. Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972-976.  https://doi.org/10.1001/archneur.59.6.972
  69. Lee SH, Kim I, Chung BC. Increased urinary level of oxidized nucleosides in patients with mild-to-moderate Alzheimer’s disease. Clin Biochem. 2007;40(13-14):936-938.  https://doi.org/10.1016/j.clinbiochem.2006.11.021
  70. Arnold SE, Lee EB, Moberg PJ, et al. Olfactory epithelium amyloid‐β and paired helical filament‐tau pathology in Alzheimer disease. Ann neurol. 2010;67(4):462-469.  https://doi.org/10.1002/ana.21910
  71. Ayala-Grosso CA, Pieruzzini R, Diaz-Solano D, et al. Amyloid-aβ Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer’s disease patients. Brain Pathology. 2015;25(2):136-145.  https://doi.org/10.1111/bpa.12169
  72. Liu Z, Kameshima N, Nanjo T, et al. Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau. J Alzheimer’s Dis. 2018;62(2):737-744.  https://doi.org/10.3233/JAD-170962
  73. Yoo SJ, Lee JH, Kim SY, et al. Differential spatial expression of peripheral olfactory neuron-derived BACE1 induces olfactory impairment by region-specific accumulation of β-amyloid oligomer. Cell Death Dis. 2017;8(8):e2977. https://doi.org/10.1038/cddis.2017.349
  74. Hock C, Golombowski S, Müller-Spahn F, et al. Histological markers in nasal mucosa of patients with Alzheimer’s disease. Eur Neurol. 1998;40(1):31-36.  https://doi.org/10.1159/000007953
  75. Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014;127(4):459-475.  https://doi.org/10.1007/s00401-014-1261-7
  76. Passali GC, Politi L, Crisanti A, et al. Tau protein detection in anosmic Alzheimer’s disease patient’s nasal secretions. Chemosensory Perception. 2015;8(4):201-206.  https://doi.org/10.1007/s12078-015-9198-3
  77. Moon J, Lee ST, Kong IG, et al. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level. Sci Rep. 2016;6:20364. https://doi.org/10.1038/srep20364

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.